Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

ClinicalTrials.gov ID: NCT07405476

Public ClinicalTrials.gov record NCT07405476. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Clinical Trial of Neoadjuvant Zanidatamab for HER2+ Localized Colorectal Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial studies how well giving zanidatamab before surgery (neoadjuvant) works in treating patients with colon and rectal cancer that is human epidermal growth factor receptor 2 positive (HER2+ve) who are planned for curative intent treatment. Zanidatamab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).

Study identification

NCT ID: NCT07405476
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Emory University; Other
Enrollment: 38 participants

Conditions and interventions

Conditions

Interventions

Biological · Procedure · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 7, 2026 (Actual)
Primary completion: Dec 18, 2028 (Estimated)
Completion: Dec 18, 2029 (Estimated)
Last update posted: Apr 17, 2026

2026 – 2029

United States locations

U.S. sites: 4
U.S. states: 1
U.S. cities: 2

Facility	City	State	ZIP	Site status
Emory University Hospital Midtown	Atlanta	Georgia	30308	Recruiting
Emory University Hospital	Atlanta	Georgia	30322	Recruiting
Emory Saint Joseph's Hospital	Atlanta	Georgia	30342	Recruiting
Emory Decatur Hospital	Decatur	Georgia	30033	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07405476, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 17, 2026 · Synced Oct 16, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07405476 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →